Načítá se...
Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever
BACKGROUND: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent ma...
Uloženo v:
| Vydáno v: | Orphanet J Rare Dis |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5450086/ https://ncbi.nlm.nih.gov/pubmed/28558744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-017-0642-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|